SlideShare a Scribd company logo
1 of 42
NEPHRON SPARING SURGERY
(NSS) IN WILMS’ TUMOR
DR ARKA BANERJEE
M.CH. RESIDENT
PAEDIATRIC SURGERY
MAMC
MODERATOR: DR S. S. PANDA
SIOP
Multicentre experience (Prospective)
To review the current SIOP NSS-experience with special emphasis on the risk of upstaging the tumor due to the
surgical technique used
Level of evidence – 2
INTRODUCTION
Most frequently occurring malignant pediatric tumor of the kidney
Bilateral – 5%
Goal of NSS: To preserve as much parenchymal reserve capacity as possible, whilst still achieving
complete surgical excision with adequate margins (to protect the patient from excessive renal
parenchymal loss in case of future contra lateral trauma or metachronous WT)
Standard procedure for uWT: Total Nephrectomy
Current therapeutic strategy (for bilateral tumors): NACT f/b Partial nephrectomy
INTRODUCTION
Most frequently occurring malignant pediatric tumor of the kidney
Bilateral – 5%
Goal of NSS: To preserve as much parenchymal reserve capacity as possible, whilst still achieving
complete surgical excision with adequate margins (to protect the patient from excessive renal
parenchymal loss in case of future contra lateral trauma or metachronous WT)
Standard procedure for uWT: Total Nephrectomy
Current therapeutic strategy (for bilateral tumors): NACT f/b Partial nephrectomy
Successful
METHODS
Nov, 2001 to July, 2012
3320 uWT
Case report forms
◦ Nephrectomy procedure
◦ Surgical approach
◦ Tumor appearance
◦ Involvement of adjacent structures
◦ Extent of resection (complete or incomplete)
◦ Summary of operative procedure (biopsy only, total nephrectomy or nephron sparing surgery)
◦ Surgical complications
◦ Pathology information – local pathologist and central review
◦ Histological subtype
◦ Tumor stage
METHODS
Tumors were staged according to the SIOP trials criteria
All patients had neo-adjuvant chemotherapy and delayed surgery followed by risk-adapted post-op
chemotherapy (and radiotherapy in stage III)
Pre-operative treatment
◦ Localized tumors – VA × 4 wks
◦ Weekly Vincristine (1.5 mg/m2)
◦ 2-weekly Actinomycin D (45 μg/m2)
◦ Metastatic tumors – VAD × 6 wks
◦ Weekly Vincristine (1.5 mg/m2)
◦ 2-weekly Actinomycin D (45 μg/m2)
◦ Doxorubicin (2 doses of 50 mg/m2)
The results between the two surgical treatment groups compared
◦ Complications
◦ Local recurrence
◦ FYS (5 year-survival) rates
Special emphasis was put to analyze the potential adverse influence of NSS on staging
STATISTICS
Patient characteristics, such as operative complications, were compared using Fisher exact tests
The association between stage distribution and the type of resection was tested with Cochran Armitage test
Wilcoxon-Mann Whitney test was used to test for differences in median volume at diagnosis and volume at surgery.
Survival curves were presented according to the Kaplan-Meier method
Event free survival (EFS): Time from the date of diagnosis to first documented disease progression/recurrence/death (of
any cause)
Overall survival (OS): Time from the date of diagnosis to death of any cause
Patients without an event (death) were censored at the date that they were last known to be alive
Time to event endpoints was compared using log-rank tests.
RESULTS
3320 pts with uWT recorded
◦ 2800 (84%) had an unequivocal surgical resection
◦ Type of surgery
◦ TN – 2709 (97%)
◦ NSS – 91 (3%)
◦ Partial Nephrectomy – 62 (68%)
◦ Wedge resection – 20 (22%)
◦ Enucleation – 4 (4%)
◦ Technical information missing concerning the type of NSS – 5 (5%)
◦ Disease
◦ Localized – 2377
◦ Metastatic – 423
◦ 2 (<1%) underwent NSS
RESULTS
Median F/U – 43 mts
◦ TN – 49.1 mts
◦ NSS – 36.9 mts
Tumor capsule rupture (No significant difference)
◦ TN – 3%
◦ NSS – 2%
Lymph node rupture – 3% (in both)
Surgical complications (No significant difference) p = 0.052
◦ TN – 137/2709 (5%)
◦ NSS – 9/91 (10%)
Type of complications – similar in both groups
RESULTS: STRATIFICATION
Post op staging
Histologic risk grouping – equally distributed in both groups
◦ All 11 patients in NSS group with high risk histology were blastemal type
STAGE TN NSS
I 1294 (48%) 59 (65%)
II 638 (24%) 13 (14%)
III 712 (26%) 12 (13%)
Missing 65 (2%) 7 (8%)
RESULTS: TUMOR VOLUME
Tumor volumes were significantly lower in NSS
◦ At diagnosis p < 0.001
◦ At surgery p < 0.001
RESULTS: NSS for Stage III tumor
12 pts in NSS group had Stage III tumor
◦ Positive margins (M+) – 8/12 (67%)
◦ 5 were M+ LN–
◦ 2 were M+ LN– but also had a tumor rupture
◦ 1 was LN positive (M+ LN+) – underwent enucleation Positive margin could be avoided with TN
◦ LN positive (M –LN+) – 3/12
◦ Rupture alone (M– LN–) – 1/12
Treatment of M+ in NSS group
◦ Conversion to TN – 3 (1 received RT also)
◦ Radiotherapy only – 3
◦ Local therapy, if given, not recorded – 2
RESULTS: TN for Stage III tumor
712 pts in TN group had Stage III tumor
◦ Positive margins (M+) – 355/712 (50%) [Tumor reaching the inked surface of resected specimen]
◦ 187 were M+ LN–
◦ 66 were M+ LN– but also had a tumor rupture
◦ 102 were M+ LN+
◦ 22/102 had a tumor rupture also
◦ LN positive (M– LN+) – 193
◦ 22 were M– LN+ and had tumor rupture also
◦ Rupture alone (M– LN–) – 50
◦ Reason unknown – 92
RESULTS: RELAPSE
Tumor relapse
◦ TN – 344 (13%)
◦ NSS – 4 (4%)
Relapse at primary site
◦ TN – 49 (2%)
◦ NSS – 1 (1%)
Relapse at primary site as well as at other sites
◦ TN – 47 (2%)
◦ NSS – 1 (1%) M+LN– with major intra-op rupture; treated with post-op RT and alive till date
RESULTS: SURVIVAL
Survival after NSS
◦ OS – 100
◦ EFS – 94.9
Survival after TN
◦ OS – 91.9 p=0.02
◦ EFS – 84.1 p=0.02
Survival after NSS in localized disease
◦ OS – 100
◦ EFS – 94.8
Survival after TN in localized disease
◦ OS – 94.4 p=0.06
◦ EFS – 86.5 p=0.06
DISCUSSION
First protocolized prospective experience with the use of NSS in the treatment of uWT
3% of all patients were subjected to NSS (Expected no of eligible pts: 5–10%)
◦ Reflects the surgeons’
◦ adherence to protocol which states that partial nephrectomy is not recommended in a classical unilateral WT (not associated with
a WT-predisposition syndrome)
◦ prudence to apply a relatively new surgical technique to uWT
Highly selective subgroup of patients treated with NSS
◦ Higher proportion of stage I tumors and smaller proportion of stage III tumors when
compared to those that underwent a TN
◦ Significantly smaller tumor volumes both at diagnosis and at surgery
Protocol guidelines stating that NSS should be restricted to small, polar or peripherally non-
infiltrating tumors were adhered to quite strictly
DISCUSSION
Rupture rate (2-3%) – not influenced by the surgical technique
More complications occurred in the NSS group (10% vs. 5% occurring in the TN group) – not
significant
◦ Expectation: different types of complications for the two surgical techniques
◦ Reflects the limitations of the standard surgical record form rather than the similarity of the
complications
No difference in EFS and OS between NSS and TN once tumor stage had been taken into
consideration
◦ Larger percentage of patients with metastatic disease in the TN group may explain the apparent
difference in favor of NSS
RECOMMENDATIONS
NSS – feasible and safe, provided recommendations on suitable tumor
configuration are adhered to
Although the low (4%) relapse rate did not contribute to mortality, one must remain
aware of the potential pitfalls that could threaten the patient
◦ The surgeon cannot predict the nodal status or histological subtype and positive nodes can
come as a surprise (although especially in small tumors that are eligible for NSS, lymph nodes
usually are tumor negative)
◦ In patients with positive nodes, the kidney remnant will be subjected to radiotherapy that
may hamper the future function of the remaining nephrons so carefully strived to secure
But what about patients with negative lymph nodes who became stage III due to a
positive surgical margin?
◦ Should usually receive radiotherapy which may not have been required if complete surgical
clearance had been achieved through total nephrectomy
RECOMMENDATIONS
Positive surgical margins may also occur after TN
◦ Reflects tumor growth outside the capsule or the surgical procedure
Goal of NSS is to preserve renal function without compromising complete tumor
resection – What is the effect of additional radiotherapy on the long term function
of the kidney remnant?
◦ Some papers point to an adverse effect of RT to the contra-lateral kidney whilst others report
the preservation thereof after radiotherapy of the kidney remnant
◦ The SIOP 2001 protocol dictates radiotherapy to the tumor bed in case of positive margins,
positive lymph nodes and/or tumor spill
◦ Insufficient evidence to know whether additional surgical therapy on top of the radiotherapy
is superior to radiotherapy alone
CONCLUSION
Nephron Sparing Surgery, a new approach for uWT has now been shown to be safe in a small
and highly selected proportion of uWT patients – concordant with the intention of the SIOP
2001 protocol
The event-free and overall survival after NSS appears to be as good as after Total Nephrectomy
in the patient group not skewed by metastatic disease with an equal local relapse rate as after
TN
The gain of nephrons after NSS still needs to be carefully weighed against the potential risk of
inducing stage III with the consequence of abdominal radiotherapy
COG
Qualitative non-pooled systematic review
Level of evidence: 1
INTRODUCTION
Most common solid renal malignancy in children
Estimated annual incidence rate – 7 to 10 cases per million (<15 years age group)
Bilateral WT – 5-7% of children with renal tumors
Mx – Multimodality therapy, including radical nephrectomy via a transperitoneal approach
Historically, nephron-sparing surgery (NSS) was reserved for bilateral WT or children with a
solitary kidney in whom preservation of renal function was mandatory
◦ Major challenge in these children was to preserve renal function while adequately treating the tumors
Mx of bilateral WT – NACT f/b Radical nephrectomy (RN) of the more involved kidney and NSS
on the less involved contralateral kidney
◦ Bilateral WT patients have been noted to have a significant risk of ESRD due to perioperative renal
insults in addition to tumor recurrence and subsequent nephrectomy
INTRODUCTION
Modern management of bilateral WT – NACT f/b NSS (first-line treatment)
Bilateral and/or syndromic WT protocol for COG
◦ 6 to 12 weeks of vincristine, dactinomycin, and doxorubicin prior to resection
◦ Following surgery, adjuvant chemotherapy and radiation therapy regimen depending on tumor histology and
staging
AREN0534 trial of COG encourages NSS in children with
◦ Bilateral WT
◦ Unilateral WT in children with syndromes which predispose to renal failure
◦ Metachronous development of WT in the contralateral kidney
Objective
◦ To examine the accumulated literature on the use of NSS among children with WT, both unilateral and bilateral
Aim
◦ Assess the reported outcomes of NSS
◦ Compare these to the current gold standard surgical treatment of WT, RN
METHODS
Electronic databases searched for studies published between 1980-2014 based upon PRISMA
guidelines
Restricted to articles retrieved under a second search for the terms “pediatric” or “child” or
“children”
Reference lists of included studies were manually screened for any additional studies
Manual search for unpublished abstracts presented at relevant scientific meetings
Included English-language studies of children (aged  18 yrs) diagnosed with Wilms tumor that
compared the outcomes or effects of NSS vs. RN
Two reviewers independently reviewed all study abstracts in duplicate with disagreements resolved
by the senior author
Full text articles appearing to meet selection criteria were reviewed and study data was abstracted
RESULTS
694 publications identified with an
additional 3 reports
◦ 118 studies were selected for full text review
◦ Exclusions
◦ 15 studies due to a focus on disease other than Wilms’
tumor
◦ 5 due to inability to extract out pediatric specific data
◦ 18 due to duplicate reporting or review of previous reports
◦ 15 due to insufficient reporting of data on RN and NSS
patients
◦ Total 66 studies met all criteria and were
included in the final review
◦ 60 (91%) – retrospective cohorts/case series (including an
administrative database analysis)
◦ 6 (9%) – prospective data
RESULTS: PATIENT COHORT
4022 patients
◦ M – 1632 (41%)
◦ Ages - < 1 mt to 18 yrs
◦ B/L – 1153 (29%)
◦ Including 4 metachronous contralateral tumours
◦ Mean size
◦ RN – 5-14 cm
◦ NSS – 1.5-9 cm
◦ NSS done in
◦ 1040 (26%) patients
◦ 1311 (32%) kidneys
◦ RN done in
◦ 2962 (74%) patients
◦ 2844 (68%) kidneys
◦ NACT given in
◦ 195 (7%) of RN pts
◦ 248 (24%) of NSS pts
RESULTS: STRATIFICATION
Variably reported
B/L WT
◦ Local stage infrequently reported
◦ Discordant local staging per kidney
Histology (similar between RN and NSS groups)
SURGERY STUDIES FAVORABLE UNFAVORABLE
Aggregate (RN/NSS) 24 86 % 14%
RN 2 92 % 8 %
NSS 8 94 % 6 %
RESULTS: STRATIFICATION
Tumor stage
◦ Patients chosen for NSS were more likely to have a lower-staged tumor than those undergoing RN
More uniform reporting standards would help elucidate the extent to which histology and stage
impact outcome and how they should be implemented in patient selection
SURGERY STUDIES STAGE I STAGE II STAGE III STAGE IV STAGE V
Aggregate
(RN/NSS)
21 33 % 37 % 19 % 5 % 7 %
RN 7 34 % 31 % 20 % 15 % -
NSS 14 49 % 32 % 18 % 0.6 % 1 %
OUTCOMES
Presented variably
◦ Direct comparison of outcomes data could not be performed
SURGERY
TUMOR RUPTURE RECURRECNCE ESRD OS
Studies
Mean
(Range)
Studies
Mean
(Range)
Studies
Mean
(Range)
Studies
Mean
(Range)
RN 3
13 %
(0 – 40 %)
14
12 %
(0 – 38 %)
12
8 %
(0 – 50 %)
24 85 %
(50 – 100 %)
NSS 7
7 %
(0 – 25 %)
33
11 %
(0 – 60 %)
28
3 %
(0 – 18 %)
35 88 %
(35 – 100 %)
OUTCOMES
Improved outcomes over time
SURGERY 1980s 2010s
RN 61 % 99 %
NSS 87 % 93 %
DISCUSSION
Most studies detailing outcomes of surgical techniques for resection of WT were retrospective cohorts and case series
Most current studies of RN and NSS patients appear to show similar tumor rupture, recurrence, ESRD and OS outcomes
between the 2 techniques
◦ Selection bias: Patients chosen for NSS are likely to be different than the average RN patient
◦ Reporting bias: Poor results with a new or controversial technique (such as NSS) are less likely to be reported than poor results with a
well-established technique (such as RN)
An RCT of RN vs. NSS would thus be likely to have a significant impact on modern management of WT
◦ Logistical issues
Adult RCC – Recent publications suggest that NSS provides a risk reduction in
◦ All cause mortality
◦ Cancer specific mortality
◦ Severe chronic kidney disease
*Supported by a systematic review which drew the same conclusion regarding malignant renal tumors less than 4.0 cm
DISCUSSION
Why NSS in uWT?
◦ Prospectful data from adult studies
◦ Increasing familiarity of surgeons/urologists with NSS
◦ ESRD was the 2nd most common cause of death among WT survivors (after cardiovascular causes)
◦ Only relevant in the context of successful cancer treatments
◦ Implies that the theoretical benefits of NSS must be considered against any potential risks in terms of
◦ Cancer recurrence
◦ EFS (event-free survival) from tumor spill or positive margins
4thNational Wilms’ Tumor Study
◦ Intraoperative tumor spill nearly doubled their risk of death (HR 1.94) as compared to patients without tumor spill
SEER, SIOP and COG
◦ Relatively few patients currently undergo NSS
◦ Benefits of NSS clearly need to be weighed against the potential downside risks of compromised oncologic outcomes
in the name of improved nephron counts
DISCUSSION: CHALLENGES
Technical considerations of removing a large tumor from a small kidney
◦ Is tumor enucleation alone sufficient?
◦ Is a margin of normal parenchyma required
◦ If yes, how much margin is required?
Longo et al – compared simple enucleation and partial nephrectomy for T1 renal masses; enucleation
was associated with
◦ Similar warm ischemia time
◦ Lower intraoperative blood loss
◦ Shorter operative time
◦ Decreased risk of positive surgical margins
Kieran et al – positive margins did not impact survival in patients with bilateral WT undergoing NSS
◦ Small study – 21 patients total, only 5 of whom had positive margins
◦ Patients with positive margins also underwent additional confounding therapy in the form of flank irradiation
DISCUSSION: CHALLENGES
Training issues in the use of NSS
◦ Most WT are treated by pediatric surgeons who may or may not have been trained in the use of NSS
during their residency or fellowship
◦ Ritchey et al –reported significant quality differences between pediatric surgeons and general surgeons in terms of WT surgical
management
◦ Differences between pediatric urologists and pediatric surgeons have recently been studied for RN with few clinically significant
differences noted
Role of NACT
◦ Reduces tumor volume
◦ Improves technical feasibility of NSS
◦ Improves surgical positive margin rates
◦ Current COG protocol (AREN0534)
◦ 6-12 weeks of preoperative chemotherapy (without biopsy, prior to surgical removal of tumor) for children with
◦ Bilateral tumors
◦ Syndromic associations
DISCUSSION: CHALLENGES
Patient selection
◦ Cost and Ferrar
◦ Only 25% of children with unilateral WT are candidates for NSS
◦ Only 1% of these children actually undergo NSS
◦  One of the goals of future research efforts should be to determine which children can
safely undergo NSS
◦ Ehrlich et al – reported on 39 patients with unilateral WT who underwent NSS
◦ 9/39 (23%) were found to have positive margins or intraoperative tumor spill – received additional chemotherapy
and radiation due to surgical factors
◦ Despite this, the FYS in those patients was 96%
◦ NSS feasibility, however, can be aided by preoperative imaging
◦ Sensitivity – 87%
◦ Specificity – 97%
◦ Accuracy – 93%
LIMITATIONS
A trial of RN and NSS would be technically challenging to plan and accomplish
Most included studies were retrospective case series with highly variable reporting quality
This level of evidence is generally recognized as suboptimal for inclusion in meta-analyses
Any comparisons of these studies will be significantly limited by their
◦ Small numbers
◦ Inconsistent reporting
◦ Inherent methodological biases of the study designs
SUMMARY
Most contemporary studies reporting the use of NSS in children with WT report similar long-
term outcomes to RN in regards to
◦ ESRD
◦ Tumor recurrence
◦ Tumor rupture
◦ OS
These studies are significantly limited by their inherent methodological flaws
No randomized controlled trial of NSS and RN use in children with WT
 Significant opportunities for future research on the use of NSS in children with WT
The short- and long-term risks and benefits of NSS and RN as “gold standard” treatment for all
children are ripe areas for future comparative effectiveness research
CONCLUSION
Most existing studies are relatively small, non-randomized, retrospective studies
Significant opportunities for future research on the use of NSS in children with WT
◦ Which children are most (and least) likely to benefit from NSS ?
◦ What is the optimal surgical technique ?
◦ Whether preoperative chemotherapy plays a role in NSS ?
◦ What is acceptable variation in the use of NSS among centers and among providers ?
Level of evidence: 5
Role of partial nephrectomy in the management of unilateral Wilms tumours is controversial
The benefits of preserving as much functioning renal tissue as possible must be balanced against
the increased risk of local recurrence
NWTSG report for bilateral Wilms tumours showed that partial nephrectomy specimens with
incomplete resection margins had a high rate of local recurrence (16%)
◦ This compares with a local recurrence rate of 3.2% after radical nephrectomy
UKW-3 trial (1991) – To ascertain the feasibility of partial nephrectomy in unilateral low grade
Wilms tumours
◦ If, after total nephrectomy, the surgeon thought that a partial nephrectomy might have been possible,
s/he was asked to mark the proposed resection line on the kidney specimen but to do a radical
nephrectomy as normal
◦ The pathologist was asked to report on whether the tumour would have been excised completely and
how much renal tissue would have remained
◦ The surgical and pathology reports of all patients entered into the UKW-3 trial (between 1st October
1991 and 30th March 2001) recorded as suitable for partial nephrectomy were studied in detail
◦ To be considered feasible for partial nephrectomy, there had to be
◦ Clear resection margins
◦ No vascular invasion
◦ No pelvic invasion
◦ At least 50% of unaffected kidney left behind
UKW-3 trial (1991)
◦ 842 patients with Wilms tumour
◦ 43 (6.5%) were considered, by the operating surgeon, as candidates for partial nephrectomy
◦ Unfortunately, there was no recorded instance when the kidney was marked
◦ The pathologist only addressed the question in 20/43
◦ 14 (70%) patients would not have had complete tumour clearance
◦ Psitive lateral resection margins (3)
◦ Tumour in vein (2)
◦ Tumour invading the renal pelvis (7)
◦ Less than 50% of normal kidney remaining (10)
◦ 12 patients had partial nephrectomy
◦ 11 patients – no information on whether the remaining kidney tissue functioned
◦ 1 patient with duplex kidney – the remaining upper pole did not function
◦ In conclusion, the question concerning partial nephrectomy was poorly addressed due to failure to
follow study protocol
◦ In the majority of cases (70%) where feasibility has been assessed, the surgeon did not accurately
predict which tumours could be resected by partial nephrectomy
◦ Difficult to see how further prospective data on this subject will be forthcoming
◦ If further studies are planned then a major effort needs to be made to get surgeons and pathologists to
rigorously co-ordinate their studies of individual kidney specimens
THANK YOU !

More Related Content

What's hot

Upper urinary tract - Urothelial cell carcinoma
Upper urinary tract - Urothelial cell carcinomaUpper urinary tract - Urothelial cell carcinoma
Upper urinary tract - Urothelial cell carcinomaGovtRoyapettahHospit
 
Carcinoma rectum
Carcinoma   rectumCarcinoma   rectum
Carcinoma rectumbarun kumar
 
CURRENT TRENDS IN Renal cell carcinoma
CURRENT TRENDS IN Renal cell carcinomaCURRENT TRENDS IN Renal cell carcinoma
CURRENT TRENDS IN Renal cell carcinomaVikas Kumar
 
Renal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And ManagementRenal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And ManagementRHMBONCO
 
Management of renal cell carcinoma and wilms' tumor
Management of renal cell carcinoma and wilms' tumor Management of renal cell carcinoma and wilms' tumor
Management of renal cell carcinoma and wilms' tumor Anil Gupta
 
Prostate carcinoma- Castrate Resistant Prostate Cancer (crpc)
Prostate  carcinoma- Castrate Resistant Prostate Cancer (crpc)Prostate  carcinoma- Castrate Resistant Prostate Cancer (crpc)
Prostate carcinoma- Castrate Resistant Prostate Cancer (crpc)GovtRoyapettahHospit
 
Bile duct injuries.slideshare
Bile duct injuries.slideshareBile duct injuries.slideshare
Bile duct injuries.slidesharedrksreenath
 
Testis carcinoma- management- rplnd
Testis  carcinoma- management- rplndTestis  carcinoma- management- rplnd
Testis carcinoma- management- rplndGovtRoyapettahHospit
 
Functional liver residue-- All we need to know
Functional liver residue-- All we need to knowFunctional liver residue-- All we need to know
Functional liver residue-- All we need to knowDr. Shashank Agrawal
 
Prostate carcinoma- diagnosis and staging
Prostate  carcinoma- diagnosis and stagingProstate  carcinoma- diagnosis and staging
Prostate carcinoma- diagnosis and stagingGovtRoyapettahHospit
 
Peritoneal Carcinomatosis : Dr Amit Dangi
Peritoneal Carcinomatosis :  Dr Amit DangiPeritoneal Carcinomatosis :  Dr Amit Dangi
Peritoneal Carcinomatosis : Dr Amit DangiDr Amit Dangi
 
Surgical Treatment of Pancreatic Cancer - Dimitris P. Korkolis
Surgical Treatment of Pancreatic Cancer - Dimitris P. KorkolisSurgical Treatment of Pancreatic Cancer - Dimitris P. Korkolis
Surgical Treatment of Pancreatic Cancer - Dimitris P. KorkolisDimitris P. Korkolis
 
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Siewhong Ho
 
Carcinoma stomach management
Carcinoma stomach   managementCarcinoma stomach   management
Carcinoma stomach managementShriyans Jain
 
RENAL CELL CARCINOMA
RENAL CELL CARCINOMARENAL CELL CARCINOMA
RENAL CELL CARCINOMAKaran Rawat
 
Bile duct injuries
Bile duct injuriesBile duct injuries
Bile duct injuriesjoemdas
 
Clinically localized prostate cancer Management
Clinically localized prostate cancer ManagementClinically localized prostate cancer Management
Clinically localized prostate cancer ManagementDr.Bhavin Vadodariya
 
Natural Orifice Transluminal Endoscopic Surgery"NOTES"
Natural Orifice Transluminal Endoscopic Surgery"NOTES"Natural Orifice Transluminal Endoscopic Surgery"NOTES"
Natural Orifice Transluminal Endoscopic Surgery"NOTES"Hisham Ahmed,M.D,PhD,MRCS
 

What's hot (20)

Upper urinary tract - Urothelial cell carcinoma
Upper urinary tract - Urothelial cell carcinomaUpper urinary tract - Urothelial cell carcinoma
Upper urinary tract - Urothelial cell carcinoma
 
Carcinoma rectum
Carcinoma   rectumCarcinoma   rectum
Carcinoma rectum
 
CURRENT TRENDS IN Renal cell carcinoma
CURRENT TRENDS IN Renal cell carcinomaCURRENT TRENDS IN Renal cell carcinoma
CURRENT TRENDS IN Renal cell carcinoma
 
Renal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And ManagementRenal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And Management
 
Management of renal cell carcinoma and wilms' tumor
Management of renal cell carcinoma and wilms' tumor Management of renal cell carcinoma and wilms' tumor
Management of renal cell carcinoma and wilms' tumor
 
Prostate carcinoma- Castrate Resistant Prostate Cancer (crpc)
Prostate  carcinoma- Castrate Resistant Prostate Cancer (crpc)Prostate  carcinoma- Castrate Resistant Prostate Cancer (crpc)
Prostate carcinoma- Castrate Resistant Prostate Cancer (crpc)
 
Bile duct injuries.slideshare
Bile duct injuries.slideshareBile duct injuries.slideshare
Bile duct injuries.slideshare
 
Testis carcinoma- management- rplnd
Testis  carcinoma- management- rplndTestis  carcinoma- management- rplnd
Testis carcinoma- management- rplnd
 
Functional liver residue-- All we need to know
Functional liver residue-- All we need to knowFunctional liver residue-- All we need to know
Functional liver residue-- All we need to know
 
Prostate carcinoma- diagnosis and staging
Prostate  carcinoma- diagnosis and stagingProstate  carcinoma- diagnosis and staging
Prostate carcinoma- diagnosis and staging
 
Peritoneal Carcinomatosis : Dr Amit Dangi
Peritoneal Carcinomatosis :  Dr Amit DangiPeritoneal Carcinomatosis :  Dr Amit Dangi
Peritoneal Carcinomatosis : Dr Amit Dangi
 
Surgical Treatment of Pancreatic Cancer - Dimitris P. Korkolis
Surgical Treatment of Pancreatic Cancer - Dimitris P. KorkolisSurgical Treatment of Pancreatic Cancer - Dimitris P. Korkolis
Surgical Treatment of Pancreatic Cancer - Dimitris P. Korkolis
 
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
 
Carcinoma stomach management
Carcinoma stomach   managementCarcinoma stomach   management
Carcinoma stomach management
 
RENAL CELL CARCINOMA
RENAL CELL CARCINOMARENAL CELL CARCINOMA
RENAL CELL CARCINOMA
 
Bile duct injuries
Bile duct injuriesBile duct injuries
Bile duct injuries
 
Clinically localized prostate cancer Management
Clinically localized prostate cancer ManagementClinically localized prostate cancer Management
Clinically localized prostate cancer Management
 
Natural Orifice Transluminal Endoscopic Surgery"NOTES"
Natural Orifice Transluminal Endoscopic Surgery"NOTES"Natural Orifice Transluminal Endoscopic Surgery"NOTES"
Natural Orifice Transluminal Endoscopic Surgery"NOTES"
 
Nephrometry
NephrometryNephrometry
Nephrometry
 
Cystic tumours of pancreas
Cystic tumours of pancreasCystic tumours of pancreas
Cystic tumours of pancreas
 

Similar to Nephron sparing surgery in wilms

ECCLU 2011 - A. Bex - Kidney cancer - Adjuvant and neo-adjuvant treatment
ECCLU 2011 - A. Bex - Kidney cancer - Adjuvant and neo-adjuvant treatmentECCLU 2011 - A. Bex - Kidney cancer - Adjuvant and neo-adjuvant treatment
ECCLU 2011 - A. Bex - Kidney cancer - Adjuvant and neo-adjuvant treatmentEuropean School of Oncology
 
1411 APLCC AHNYC Tri Bimodality N2
1411 APLCC AHNYC Tri Bimodality N21411 APLCC AHNYC Tri Bimodality N2
1411 APLCC AHNYC Tri Bimodality N2Yong Chan Ahn
 
Management of Renal Cell Carcinoma ppt.pptx
Management of Renal Cell Carcinoma ppt.pptxManagement of Renal Cell Carcinoma ppt.pptx
Management of Renal Cell Carcinoma ppt.pptxAtulGupta369
 
Head & neck cancer
Head & neck cancerHead & neck cancer
Head & neck cancerradiosurgery
 
Chemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptxChemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptxAtulGupta369
 
Soft tissue sarcoma- Unplanned excisions.
Soft tissue sarcoma- Unplanned excisions.Soft tissue sarcoma- Unplanned excisions.
Soft tissue sarcoma- Unplanned excisions.Rohit Kabre
 
M crc ppt
M crc pptM crc ppt
M crc pptmadurai
 
Radiotherapy for bladder cancers
Radiotherapy for bladder cancersRadiotherapy for bladder cancers
Radiotherapy for bladder cancersAshutosh Mukherji
 
Evaluation and Management of Retroperitoneal Sarcoma.pptx
Evaluation and Management of Retroperitoneal Sarcoma.pptxEvaluation and Management of Retroperitoneal Sarcoma.pptx
Evaluation and Management of Retroperitoneal Sarcoma.pptxmasoom parwez
 
Pancreatic Cancer
Pancreatic CancerPancreatic Cancer
Pancreatic Cancerspa718
 
Post mastectomy Radiotherapy with trails
Post mastectomy Radiotherapy with trailsPost mastectomy Radiotherapy with trails
Post mastectomy Radiotherapy with trailsAnban Bala
 
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdf
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdfMANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdf
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdfadhilaamariyil
 
Esophageal cancer-role of RT
Esophageal cancer-role of RTEsophageal cancer-role of RT
Esophageal cancer-role of RTBharti Devnani
 
Uveal Melanoma Liver Metastases - 2019 CURE OM Symposium
Uveal Melanoma Liver Metastases - 2019 CURE OM SymposiumUveal Melanoma Liver Metastases - 2019 CURE OM Symposium
Uveal Melanoma Liver Metastases - 2019 CURE OM SymposiumMelanoma Research Foundation
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast CancerMohamed Abdulla
 
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCERROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCERKanhu Charan
 
03 suh lung sbrt hyderabad feb 2013 (cancer ci 2013) john h. suh
03 suh lung sbrt hyderabad feb 2013 (cancer ci 2013) john h. suh03 suh lung sbrt hyderabad feb 2013 (cancer ci 2013) john h. suh
03 suh lung sbrt hyderabad feb 2013 (cancer ci 2013) john h. suhDr. Vijay Anand P. Reddy
 

Similar to Nephron sparing surgery in wilms (20)

ECCLU 2011 - A. Bex - Kidney cancer - Adjuvant and neo-adjuvant treatment
ECCLU 2011 - A. Bex - Kidney cancer - Adjuvant and neo-adjuvant treatmentECCLU 2011 - A. Bex - Kidney cancer - Adjuvant and neo-adjuvant treatment
ECCLU 2011 - A. Bex - Kidney cancer - Adjuvant and neo-adjuvant treatment
 
1411 APLCC AHNYC Tri Bimodality N2
1411 APLCC AHNYC Tri Bimodality N21411 APLCC AHNYC Tri Bimodality N2
1411 APLCC AHNYC Tri Bimodality N2
 
Management of Renal Cell Carcinoma ppt.pptx
Management of Renal Cell Carcinoma ppt.pptxManagement of Renal Cell Carcinoma ppt.pptx
Management of Renal Cell Carcinoma ppt.pptx
 
Head & neck cancer
Head & neck cancerHead & neck cancer
Head & neck cancer
 
Chemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptxChemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptx
 
Soft tissue sarcoma- Unplanned excisions.
Soft tissue sarcoma- Unplanned excisions.Soft tissue sarcoma- Unplanned excisions.
Soft tissue sarcoma- Unplanned excisions.
 
M crc ppt
M crc pptM crc ppt
M crc ppt
 
Cytoreductive nephrectomy
Cytoreductive nephrectomyCytoreductive nephrectomy
Cytoreductive nephrectomy
 
Radiotherapy for bladder cancers
Radiotherapy for bladder cancersRadiotherapy for bladder cancers
Radiotherapy for bladder cancers
 
Evaluation and Management of Retroperitoneal Sarcoma.pptx
Evaluation and Management of Retroperitoneal Sarcoma.pptxEvaluation and Management of Retroperitoneal Sarcoma.pptx
Evaluation and Management of Retroperitoneal Sarcoma.pptx
 
Pancreatic Cancer
Pancreatic CancerPancreatic Cancer
Pancreatic Cancer
 
Post mastectomy Radiotherapy with trails
Post mastectomy Radiotherapy with trailsPost mastectomy Radiotherapy with trails
Post mastectomy Radiotherapy with trails
 
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdf
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdfMANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdf
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdf
 
Ewings Sarcoma
Ewings SarcomaEwings Sarcoma
Ewings Sarcoma
 
Esophageal cancer-role of RT
Esophageal cancer-role of RTEsophageal cancer-role of RT
Esophageal cancer-role of RT
 
Journal club
Journal clubJournal club
Journal club
 
Uveal Melanoma Liver Metastases - 2019 CURE OM Symposium
Uveal Melanoma Liver Metastases - 2019 CURE OM SymposiumUveal Melanoma Liver Metastases - 2019 CURE OM Symposium
Uveal Melanoma Liver Metastases - 2019 CURE OM Symposium
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast Cancer
 
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCERROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
 
03 suh lung sbrt hyderabad feb 2013 (cancer ci 2013) john h. suh
03 suh lung sbrt hyderabad feb 2013 (cancer ci 2013) john h. suh03 suh lung sbrt hyderabad feb 2013 (cancer ci 2013) john h. suh
03 suh lung sbrt hyderabad feb 2013 (cancer ci 2013) john h. suh
 

More from DrArka

Surgical outcomes of post traumatic posterior urethral strictures in children
Surgical outcomes of post traumatic posterior urethral strictures in childrenSurgical outcomes of post traumatic posterior urethral strictures in children
Surgical outcomes of post traumatic posterior urethral strictures in childrenDrArka
 
Soft tissue and envenomation injuries
Soft tissue and envenomation injuriesSoft tissue and envenomation injuries
Soft tissue and envenomation injuriesDrArka
 
Principles of radiation therapy
Principles of radiation therapyPrinciples of radiation therapy
Principles of radiation therapyDrArka
 
Paediatric Hepatocellular carcinoma
Paediatric Hepatocellular carcinomaPaediatric Hepatocellular carcinoma
Paediatric Hepatocellular carcinomaDrArka
 
Future directions in neuroblastoma
Future directions in neuroblastomaFuture directions in neuroblastoma
Future directions in neuroblastomaDrArka
 
Chemotherapy and radiotherapy in wilms' tumor and late effects
Chemotherapy and radiotherapy in wilms' tumor and late effectsChemotherapy and radiotherapy in wilms' tumor and late effects
Chemotherapy and radiotherapy in wilms' tumor and late effectsDrArka
 
Paediatric Abdominal Solid organ injury
Paediatric Abdominal Solid organ injuryPaediatric Abdominal Solid organ injury
Paediatric Abdominal Solid organ injuryDrArka
 

More from DrArka (7)

Surgical outcomes of post traumatic posterior urethral strictures in children
Surgical outcomes of post traumatic posterior urethral strictures in childrenSurgical outcomes of post traumatic posterior urethral strictures in children
Surgical outcomes of post traumatic posterior urethral strictures in children
 
Soft tissue and envenomation injuries
Soft tissue and envenomation injuriesSoft tissue and envenomation injuries
Soft tissue and envenomation injuries
 
Principles of radiation therapy
Principles of radiation therapyPrinciples of radiation therapy
Principles of radiation therapy
 
Paediatric Hepatocellular carcinoma
Paediatric Hepatocellular carcinomaPaediatric Hepatocellular carcinoma
Paediatric Hepatocellular carcinoma
 
Future directions in neuroblastoma
Future directions in neuroblastomaFuture directions in neuroblastoma
Future directions in neuroblastoma
 
Chemotherapy and radiotherapy in wilms' tumor and late effects
Chemotherapy and radiotherapy in wilms' tumor and late effectsChemotherapy and radiotherapy in wilms' tumor and late effects
Chemotherapy and radiotherapy in wilms' tumor and late effects
 
Paediatric Abdominal Solid organ injury
Paediatric Abdominal Solid organ injuryPaediatric Abdominal Solid organ injury
Paediatric Abdominal Solid organ injury
 

Recently uploaded

Bangalore Call Girls Nelamangala Number 7001035870 Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 7001035870  Meetin With Bangalore Esc...Bangalore Call Girls Nelamangala Number 7001035870  Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 7001035870 Meetin With Bangalore Esc...narwatsonia7
 
Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...
Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...
Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...narwatsonia7
 
VIP Call Girls Pune Sanjana 9907093804 Short 1500 Night 6000 Best call girls ...
VIP Call Girls Pune Sanjana 9907093804 Short 1500 Night 6000 Best call girls ...VIP Call Girls Pune Sanjana 9907093804 Short 1500 Night 6000 Best call girls ...
VIP Call Girls Pune Sanjana 9907093804 Short 1500 Night 6000 Best call girls ...Miss joya
 
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune) Girls Service
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune)  Girls ServiceCALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune)  Girls Service
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune) Girls ServiceMiss joya
 
Bangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% SafeBangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% Safenarwatsonia7
 
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Nandini 7001305949 Independent Escort Service BangaloreCall Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalorenarwatsonia7
 
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls JaipurCall Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipurparulsinha
 
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoy
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night EnjoyCall Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoy
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoybabeytanya
 
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...CALL GIRLS
 
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort ServiceCall Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Serviceparulsinha
 
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...Miss joya
 
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...Garima Khatri
 
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...Taniya Sharma
 
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...astropune
 
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...Miss joya
 
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...Call girls in Ahmedabad High profile
 
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escorts
VIP Call Girls Indore Kirti 💚😋  9256729539 🚀 Indore EscortsVIP Call Girls Indore Kirti 💚😋  9256729539 🚀 Indore Escorts
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escortsaditipandeya
 
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...Miss joya
 
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls DelhiRussian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls DelhiAlinaDevecerski
 

Recently uploaded (20)

Bangalore Call Girls Nelamangala Number 7001035870 Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 7001035870  Meetin With Bangalore Esc...Bangalore Call Girls Nelamangala Number 7001035870  Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 7001035870 Meetin With Bangalore Esc...
 
Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...
Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...
Russian Call Girls in Bangalore Manisha 7001305949 Independent Escort Service...
 
VIP Call Girls Pune Sanjana 9907093804 Short 1500 Night 6000 Best call girls ...
VIP Call Girls Pune Sanjana 9907093804 Short 1500 Night 6000 Best call girls ...VIP Call Girls Pune Sanjana 9907093804 Short 1500 Night 6000 Best call girls ...
VIP Call Girls Pune Sanjana 9907093804 Short 1500 Night 6000 Best call girls ...
 
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune) Girls Service
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune)  Girls ServiceCALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune)  Girls Service
CALL ON ➥9907093804 🔝 Call Girls Hadapsar ( Pune) Girls Service
 
Bangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% SafeBangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% Safe
Bangalore Call Girls Marathahalli 📞 9907093804 High Profile Service 100% Safe
 
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Nandini 7001305949 Independent Escort Service BangaloreCall Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
 
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCREscort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
 
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls JaipurCall Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
 
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoy
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night EnjoyCall Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoy
Call Girl Number in Vashi Mumbai📲 9833363713 💞 Full Night Enjoy
 
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
 
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort ServiceCall Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
 
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
 
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
 
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
 
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
 
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...
Russian Call Girls in Pune Tanvi 9907093804 Short 1500 Night 6000 Best call g...
 
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...
Call Girls Service Navi Mumbai Samaira 8617697112 Independent Escort Service ...
 
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escorts
VIP Call Girls Indore Kirti 💚😋  9256729539 🚀 Indore EscortsVIP Call Girls Indore Kirti 💚😋  9256729539 🚀 Indore Escorts
VIP Call Girls Indore Kirti 💚😋 9256729539 🚀 Indore Escorts
 
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
 
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls DelhiRussian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
 

Nephron sparing surgery in wilms

  • 1. NEPHRON SPARING SURGERY (NSS) IN WILMS’ TUMOR DR ARKA BANERJEE M.CH. RESIDENT PAEDIATRIC SURGERY MAMC MODERATOR: DR S. S. PANDA
  • 2. SIOP Multicentre experience (Prospective) To review the current SIOP NSS-experience with special emphasis on the risk of upstaging the tumor due to the surgical technique used Level of evidence – 2
  • 3. INTRODUCTION Most frequently occurring malignant pediatric tumor of the kidney Bilateral – 5% Goal of NSS: To preserve as much parenchymal reserve capacity as possible, whilst still achieving complete surgical excision with adequate margins (to protect the patient from excessive renal parenchymal loss in case of future contra lateral trauma or metachronous WT) Standard procedure for uWT: Total Nephrectomy Current therapeutic strategy (for bilateral tumors): NACT f/b Partial nephrectomy
  • 4. INTRODUCTION Most frequently occurring malignant pediatric tumor of the kidney Bilateral – 5% Goal of NSS: To preserve as much parenchymal reserve capacity as possible, whilst still achieving complete surgical excision with adequate margins (to protect the patient from excessive renal parenchymal loss in case of future contra lateral trauma or metachronous WT) Standard procedure for uWT: Total Nephrectomy Current therapeutic strategy (for bilateral tumors): NACT f/b Partial nephrectomy Successful
  • 5. METHODS Nov, 2001 to July, 2012 3320 uWT Case report forms ◦ Nephrectomy procedure ◦ Surgical approach ◦ Tumor appearance ◦ Involvement of adjacent structures ◦ Extent of resection (complete or incomplete) ◦ Summary of operative procedure (biopsy only, total nephrectomy or nephron sparing surgery) ◦ Surgical complications ◦ Pathology information – local pathologist and central review ◦ Histological subtype ◦ Tumor stage
  • 6. METHODS Tumors were staged according to the SIOP trials criteria All patients had neo-adjuvant chemotherapy and delayed surgery followed by risk-adapted post-op chemotherapy (and radiotherapy in stage III) Pre-operative treatment ◦ Localized tumors – VA × 4 wks ◦ Weekly Vincristine (1.5 mg/m2) ◦ 2-weekly Actinomycin D (45 μg/m2) ◦ Metastatic tumors – VAD × 6 wks ◦ Weekly Vincristine (1.5 mg/m2) ◦ 2-weekly Actinomycin D (45 μg/m2) ◦ Doxorubicin (2 doses of 50 mg/m2) The results between the two surgical treatment groups compared ◦ Complications ◦ Local recurrence ◦ FYS (5 year-survival) rates Special emphasis was put to analyze the potential adverse influence of NSS on staging
  • 7. STATISTICS Patient characteristics, such as operative complications, were compared using Fisher exact tests The association between stage distribution and the type of resection was tested with Cochran Armitage test Wilcoxon-Mann Whitney test was used to test for differences in median volume at diagnosis and volume at surgery. Survival curves were presented according to the Kaplan-Meier method Event free survival (EFS): Time from the date of diagnosis to first documented disease progression/recurrence/death (of any cause) Overall survival (OS): Time from the date of diagnosis to death of any cause Patients without an event (death) were censored at the date that they were last known to be alive Time to event endpoints was compared using log-rank tests.
  • 8. RESULTS 3320 pts with uWT recorded ◦ 2800 (84%) had an unequivocal surgical resection ◦ Type of surgery ◦ TN – 2709 (97%) ◦ NSS – 91 (3%) ◦ Partial Nephrectomy – 62 (68%) ◦ Wedge resection – 20 (22%) ◦ Enucleation – 4 (4%) ◦ Technical information missing concerning the type of NSS – 5 (5%) ◦ Disease ◦ Localized – 2377 ◦ Metastatic – 423 ◦ 2 (<1%) underwent NSS
  • 9. RESULTS Median F/U – 43 mts ◦ TN – 49.1 mts ◦ NSS – 36.9 mts Tumor capsule rupture (No significant difference) ◦ TN – 3% ◦ NSS – 2% Lymph node rupture – 3% (in both) Surgical complications (No significant difference) p = 0.052 ◦ TN – 137/2709 (5%) ◦ NSS – 9/91 (10%) Type of complications – similar in both groups
  • 10. RESULTS: STRATIFICATION Post op staging Histologic risk grouping – equally distributed in both groups ◦ All 11 patients in NSS group with high risk histology were blastemal type STAGE TN NSS I 1294 (48%) 59 (65%) II 638 (24%) 13 (14%) III 712 (26%) 12 (13%) Missing 65 (2%) 7 (8%)
  • 11. RESULTS: TUMOR VOLUME Tumor volumes were significantly lower in NSS ◦ At diagnosis p < 0.001 ◦ At surgery p < 0.001
  • 12. RESULTS: NSS for Stage III tumor 12 pts in NSS group had Stage III tumor ◦ Positive margins (M+) – 8/12 (67%) ◦ 5 were M+ LN– ◦ 2 were M+ LN– but also had a tumor rupture ◦ 1 was LN positive (M+ LN+) – underwent enucleation Positive margin could be avoided with TN ◦ LN positive (M –LN+) – 3/12 ◦ Rupture alone (M– LN–) – 1/12 Treatment of M+ in NSS group ◦ Conversion to TN – 3 (1 received RT also) ◦ Radiotherapy only – 3 ◦ Local therapy, if given, not recorded – 2
  • 13. RESULTS: TN for Stage III tumor 712 pts in TN group had Stage III tumor ◦ Positive margins (M+) – 355/712 (50%) [Tumor reaching the inked surface of resected specimen] ◦ 187 were M+ LN– ◦ 66 were M+ LN– but also had a tumor rupture ◦ 102 were M+ LN+ ◦ 22/102 had a tumor rupture also ◦ LN positive (M– LN+) – 193 ◦ 22 were M– LN+ and had tumor rupture also ◦ Rupture alone (M– LN–) – 50 ◦ Reason unknown – 92
  • 14. RESULTS: RELAPSE Tumor relapse ◦ TN – 344 (13%) ◦ NSS – 4 (4%) Relapse at primary site ◦ TN – 49 (2%) ◦ NSS – 1 (1%) Relapse at primary site as well as at other sites ◦ TN – 47 (2%) ◦ NSS – 1 (1%) M+LN– with major intra-op rupture; treated with post-op RT and alive till date
  • 15. RESULTS: SURVIVAL Survival after NSS ◦ OS – 100 ◦ EFS – 94.9 Survival after TN ◦ OS – 91.9 p=0.02 ◦ EFS – 84.1 p=0.02 Survival after NSS in localized disease ◦ OS – 100 ◦ EFS – 94.8 Survival after TN in localized disease ◦ OS – 94.4 p=0.06 ◦ EFS – 86.5 p=0.06
  • 16. DISCUSSION First protocolized prospective experience with the use of NSS in the treatment of uWT 3% of all patients were subjected to NSS (Expected no of eligible pts: 5–10%) ◦ Reflects the surgeons’ ◦ adherence to protocol which states that partial nephrectomy is not recommended in a classical unilateral WT (not associated with a WT-predisposition syndrome) ◦ prudence to apply a relatively new surgical technique to uWT Highly selective subgroup of patients treated with NSS ◦ Higher proportion of stage I tumors and smaller proportion of stage III tumors when compared to those that underwent a TN ◦ Significantly smaller tumor volumes both at diagnosis and at surgery Protocol guidelines stating that NSS should be restricted to small, polar or peripherally non- infiltrating tumors were adhered to quite strictly
  • 17. DISCUSSION Rupture rate (2-3%) – not influenced by the surgical technique More complications occurred in the NSS group (10% vs. 5% occurring in the TN group) – not significant ◦ Expectation: different types of complications for the two surgical techniques ◦ Reflects the limitations of the standard surgical record form rather than the similarity of the complications No difference in EFS and OS between NSS and TN once tumor stage had been taken into consideration ◦ Larger percentage of patients with metastatic disease in the TN group may explain the apparent difference in favor of NSS
  • 18. RECOMMENDATIONS NSS – feasible and safe, provided recommendations on suitable tumor configuration are adhered to Although the low (4%) relapse rate did not contribute to mortality, one must remain aware of the potential pitfalls that could threaten the patient ◦ The surgeon cannot predict the nodal status or histological subtype and positive nodes can come as a surprise (although especially in small tumors that are eligible for NSS, lymph nodes usually are tumor negative) ◦ In patients with positive nodes, the kidney remnant will be subjected to radiotherapy that may hamper the future function of the remaining nephrons so carefully strived to secure But what about patients with negative lymph nodes who became stage III due to a positive surgical margin? ◦ Should usually receive radiotherapy which may not have been required if complete surgical clearance had been achieved through total nephrectomy
  • 19. RECOMMENDATIONS Positive surgical margins may also occur after TN ◦ Reflects tumor growth outside the capsule or the surgical procedure Goal of NSS is to preserve renal function without compromising complete tumor resection – What is the effect of additional radiotherapy on the long term function of the kidney remnant? ◦ Some papers point to an adverse effect of RT to the contra-lateral kidney whilst others report the preservation thereof after radiotherapy of the kidney remnant ◦ The SIOP 2001 protocol dictates radiotherapy to the tumor bed in case of positive margins, positive lymph nodes and/or tumor spill ◦ Insufficient evidence to know whether additional surgical therapy on top of the radiotherapy is superior to radiotherapy alone
  • 20. CONCLUSION Nephron Sparing Surgery, a new approach for uWT has now been shown to be safe in a small and highly selected proportion of uWT patients – concordant with the intention of the SIOP 2001 protocol The event-free and overall survival after NSS appears to be as good as after Total Nephrectomy in the patient group not skewed by metastatic disease with an equal local relapse rate as after TN The gain of nephrons after NSS still needs to be carefully weighed against the potential risk of inducing stage III with the consequence of abdominal radiotherapy
  • 21. COG Qualitative non-pooled systematic review Level of evidence: 1
  • 22. INTRODUCTION Most common solid renal malignancy in children Estimated annual incidence rate – 7 to 10 cases per million (<15 years age group) Bilateral WT – 5-7% of children with renal tumors Mx – Multimodality therapy, including radical nephrectomy via a transperitoneal approach Historically, nephron-sparing surgery (NSS) was reserved for bilateral WT or children with a solitary kidney in whom preservation of renal function was mandatory ◦ Major challenge in these children was to preserve renal function while adequately treating the tumors Mx of bilateral WT – NACT f/b Radical nephrectomy (RN) of the more involved kidney and NSS on the less involved contralateral kidney ◦ Bilateral WT patients have been noted to have a significant risk of ESRD due to perioperative renal insults in addition to tumor recurrence and subsequent nephrectomy
  • 23. INTRODUCTION Modern management of bilateral WT – NACT f/b NSS (first-line treatment) Bilateral and/or syndromic WT protocol for COG ◦ 6 to 12 weeks of vincristine, dactinomycin, and doxorubicin prior to resection ◦ Following surgery, adjuvant chemotherapy and radiation therapy regimen depending on tumor histology and staging AREN0534 trial of COG encourages NSS in children with ◦ Bilateral WT ◦ Unilateral WT in children with syndromes which predispose to renal failure ◦ Metachronous development of WT in the contralateral kidney Objective ◦ To examine the accumulated literature on the use of NSS among children with WT, both unilateral and bilateral Aim ◦ Assess the reported outcomes of NSS ◦ Compare these to the current gold standard surgical treatment of WT, RN
  • 24. METHODS Electronic databases searched for studies published between 1980-2014 based upon PRISMA guidelines Restricted to articles retrieved under a second search for the terms “pediatric” or “child” or “children” Reference lists of included studies were manually screened for any additional studies Manual search for unpublished abstracts presented at relevant scientific meetings Included English-language studies of children (aged  18 yrs) diagnosed with Wilms tumor that compared the outcomes or effects of NSS vs. RN Two reviewers independently reviewed all study abstracts in duplicate with disagreements resolved by the senior author Full text articles appearing to meet selection criteria were reviewed and study data was abstracted
  • 25. RESULTS 694 publications identified with an additional 3 reports ◦ 118 studies were selected for full text review ◦ Exclusions ◦ 15 studies due to a focus on disease other than Wilms’ tumor ◦ 5 due to inability to extract out pediatric specific data ◦ 18 due to duplicate reporting or review of previous reports ◦ 15 due to insufficient reporting of data on RN and NSS patients ◦ Total 66 studies met all criteria and were included in the final review ◦ 60 (91%) – retrospective cohorts/case series (including an administrative database analysis) ◦ 6 (9%) – prospective data
  • 26. RESULTS: PATIENT COHORT 4022 patients ◦ M – 1632 (41%) ◦ Ages - < 1 mt to 18 yrs ◦ B/L – 1153 (29%) ◦ Including 4 metachronous contralateral tumours ◦ Mean size ◦ RN – 5-14 cm ◦ NSS – 1.5-9 cm ◦ NSS done in ◦ 1040 (26%) patients ◦ 1311 (32%) kidneys ◦ RN done in ◦ 2962 (74%) patients ◦ 2844 (68%) kidneys ◦ NACT given in ◦ 195 (7%) of RN pts ◦ 248 (24%) of NSS pts
  • 27. RESULTS: STRATIFICATION Variably reported B/L WT ◦ Local stage infrequently reported ◦ Discordant local staging per kidney Histology (similar between RN and NSS groups) SURGERY STUDIES FAVORABLE UNFAVORABLE Aggregate (RN/NSS) 24 86 % 14% RN 2 92 % 8 % NSS 8 94 % 6 %
  • 28. RESULTS: STRATIFICATION Tumor stage ◦ Patients chosen for NSS were more likely to have a lower-staged tumor than those undergoing RN More uniform reporting standards would help elucidate the extent to which histology and stage impact outcome and how they should be implemented in patient selection SURGERY STUDIES STAGE I STAGE II STAGE III STAGE IV STAGE V Aggregate (RN/NSS) 21 33 % 37 % 19 % 5 % 7 % RN 7 34 % 31 % 20 % 15 % - NSS 14 49 % 32 % 18 % 0.6 % 1 %
  • 29. OUTCOMES Presented variably ◦ Direct comparison of outcomes data could not be performed SURGERY TUMOR RUPTURE RECURRECNCE ESRD OS Studies Mean (Range) Studies Mean (Range) Studies Mean (Range) Studies Mean (Range) RN 3 13 % (0 – 40 %) 14 12 % (0 – 38 %) 12 8 % (0 – 50 %) 24 85 % (50 – 100 %) NSS 7 7 % (0 – 25 %) 33 11 % (0 – 60 %) 28 3 % (0 – 18 %) 35 88 % (35 – 100 %)
  • 30. OUTCOMES Improved outcomes over time SURGERY 1980s 2010s RN 61 % 99 % NSS 87 % 93 %
  • 31. DISCUSSION Most studies detailing outcomes of surgical techniques for resection of WT were retrospective cohorts and case series Most current studies of RN and NSS patients appear to show similar tumor rupture, recurrence, ESRD and OS outcomes between the 2 techniques ◦ Selection bias: Patients chosen for NSS are likely to be different than the average RN patient ◦ Reporting bias: Poor results with a new or controversial technique (such as NSS) are less likely to be reported than poor results with a well-established technique (such as RN) An RCT of RN vs. NSS would thus be likely to have a significant impact on modern management of WT ◦ Logistical issues Adult RCC – Recent publications suggest that NSS provides a risk reduction in ◦ All cause mortality ◦ Cancer specific mortality ◦ Severe chronic kidney disease *Supported by a systematic review which drew the same conclusion regarding malignant renal tumors less than 4.0 cm
  • 32. DISCUSSION Why NSS in uWT? ◦ Prospectful data from adult studies ◦ Increasing familiarity of surgeons/urologists with NSS ◦ ESRD was the 2nd most common cause of death among WT survivors (after cardiovascular causes) ◦ Only relevant in the context of successful cancer treatments ◦ Implies that the theoretical benefits of NSS must be considered against any potential risks in terms of ◦ Cancer recurrence ◦ EFS (event-free survival) from tumor spill or positive margins 4thNational Wilms’ Tumor Study ◦ Intraoperative tumor spill nearly doubled their risk of death (HR 1.94) as compared to patients without tumor spill SEER, SIOP and COG ◦ Relatively few patients currently undergo NSS ◦ Benefits of NSS clearly need to be weighed against the potential downside risks of compromised oncologic outcomes in the name of improved nephron counts
  • 33. DISCUSSION: CHALLENGES Technical considerations of removing a large tumor from a small kidney ◦ Is tumor enucleation alone sufficient? ◦ Is a margin of normal parenchyma required ◦ If yes, how much margin is required? Longo et al – compared simple enucleation and partial nephrectomy for T1 renal masses; enucleation was associated with ◦ Similar warm ischemia time ◦ Lower intraoperative blood loss ◦ Shorter operative time ◦ Decreased risk of positive surgical margins Kieran et al – positive margins did not impact survival in patients with bilateral WT undergoing NSS ◦ Small study – 21 patients total, only 5 of whom had positive margins ◦ Patients with positive margins also underwent additional confounding therapy in the form of flank irradiation
  • 34. DISCUSSION: CHALLENGES Training issues in the use of NSS ◦ Most WT are treated by pediatric surgeons who may or may not have been trained in the use of NSS during their residency or fellowship ◦ Ritchey et al –reported significant quality differences between pediatric surgeons and general surgeons in terms of WT surgical management ◦ Differences between pediatric urologists and pediatric surgeons have recently been studied for RN with few clinically significant differences noted Role of NACT ◦ Reduces tumor volume ◦ Improves technical feasibility of NSS ◦ Improves surgical positive margin rates ◦ Current COG protocol (AREN0534) ◦ 6-12 weeks of preoperative chemotherapy (without biopsy, prior to surgical removal of tumor) for children with ◦ Bilateral tumors ◦ Syndromic associations
  • 35. DISCUSSION: CHALLENGES Patient selection ◦ Cost and Ferrar ◦ Only 25% of children with unilateral WT are candidates for NSS ◦ Only 1% of these children actually undergo NSS ◦  One of the goals of future research efforts should be to determine which children can safely undergo NSS ◦ Ehrlich et al – reported on 39 patients with unilateral WT who underwent NSS ◦ 9/39 (23%) were found to have positive margins or intraoperative tumor spill – received additional chemotherapy and radiation due to surgical factors ◦ Despite this, the FYS in those patients was 96% ◦ NSS feasibility, however, can be aided by preoperative imaging ◦ Sensitivity – 87% ◦ Specificity – 97% ◦ Accuracy – 93%
  • 36. LIMITATIONS A trial of RN and NSS would be technically challenging to plan and accomplish Most included studies were retrospective case series with highly variable reporting quality This level of evidence is generally recognized as suboptimal for inclusion in meta-analyses Any comparisons of these studies will be significantly limited by their ◦ Small numbers ◦ Inconsistent reporting ◦ Inherent methodological biases of the study designs
  • 37. SUMMARY Most contemporary studies reporting the use of NSS in children with WT report similar long- term outcomes to RN in regards to ◦ ESRD ◦ Tumor recurrence ◦ Tumor rupture ◦ OS These studies are significantly limited by their inherent methodological flaws No randomized controlled trial of NSS and RN use in children with WT  Significant opportunities for future research on the use of NSS in children with WT The short- and long-term risks and benefits of NSS and RN as “gold standard” treatment for all children are ripe areas for future comparative effectiveness research
  • 38. CONCLUSION Most existing studies are relatively small, non-randomized, retrospective studies Significant opportunities for future research on the use of NSS in children with WT ◦ Which children are most (and least) likely to benefit from NSS ? ◦ What is the optimal surgical technique ? ◦ Whether preoperative chemotherapy plays a role in NSS ? ◦ What is acceptable variation in the use of NSS among centers and among providers ?
  • 40. Role of partial nephrectomy in the management of unilateral Wilms tumours is controversial The benefits of preserving as much functioning renal tissue as possible must be balanced against the increased risk of local recurrence NWTSG report for bilateral Wilms tumours showed that partial nephrectomy specimens with incomplete resection margins had a high rate of local recurrence (16%) ◦ This compares with a local recurrence rate of 3.2% after radical nephrectomy UKW-3 trial (1991) – To ascertain the feasibility of partial nephrectomy in unilateral low grade Wilms tumours ◦ If, after total nephrectomy, the surgeon thought that a partial nephrectomy might have been possible, s/he was asked to mark the proposed resection line on the kidney specimen but to do a radical nephrectomy as normal ◦ The pathologist was asked to report on whether the tumour would have been excised completely and how much renal tissue would have remained ◦ The surgical and pathology reports of all patients entered into the UKW-3 trial (between 1st October 1991 and 30th March 2001) recorded as suitable for partial nephrectomy were studied in detail ◦ To be considered feasible for partial nephrectomy, there had to be ◦ Clear resection margins ◦ No vascular invasion ◦ No pelvic invasion ◦ At least 50% of unaffected kidney left behind
  • 41. UKW-3 trial (1991) ◦ 842 patients with Wilms tumour ◦ 43 (6.5%) were considered, by the operating surgeon, as candidates for partial nephrectomy ◦ Unfortunately, there was no recorded instance when the kidney was marked ◦ The pathologist only addressed the question in 20/43 ◦ 14 (70%) patients would not have had complete tumour clearance ◦ Psitive lateral resection margins (3) ◦ Tumour in vein (2) ◦ Tumour invading the renal pelvis (7) ◦ Less than 50% of normal kidney remaining (10) ◦ 12 patients had partial nephrectomy ◦ 11 patients – no information on whether the remaining kidney tissue functioned ◦ 1 patient with duplex kidney – the remaining upper pole did not function ◦ In conclusion, the question concerning partial nephrectomy was poorly addressed due to failure to follow study protocol ◦ In the majority of cases (70%) where feasibility has been assessed, the surgeon did not accurately predict which tumours could be resected by partial nephrectomy ◦ Difficult to see how further prospective data on this subject will be forthcoming ◦ If further studies are planned then a major effort needs to be made to get surgeons and pathologists to rigorously co-ordinate their studies of individual kidney specimens